Industry breathes sigh of relief as government drops generic substitution plans for England
This article was originally published in SRA
The UK coalition government has dropped plans to introduce automatic generic substitution in England after a consultation on the proposals revealed stakeholder concern that the plans could risk patient safety and scepticism at how much the scheme could actually save1,2. The R&D-based pharmaceutical industry appears to be relieved.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.